0001127602-13-005609.txt : 20130212
0001127602-13-005609.hdr.sgml : 20130212
20130212170050
ACCESSION NUMBER: 0001127602-13-005609
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130210
FILED AS OF DATE: 20130212
DATE AS OF CHANGE: 20130212
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC
CENTRAL INDEX KEY: 0001022079
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 161387862
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 GIRALDA FARMS
CITY: MADISON
STATE: NJ
ZIP: 07940
BUSINESS PHONE: 9735202700
MAIL ADDRESS:
STREET 1: 3 GIRALDA FARMS
CITY: MADISON
STATE: NJ
ZIP: 07940
FORMER COMPANY:
FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC
DATE OF NAME CHANGE: 19960903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PREVOZNIK MICHAEL E
CENTRAL INDEX KEY: 0001222679
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12215
FILM NUMBER: 13598002
MAIL ADDRESS:
STREET 1: 3 GIRALDA FARMS
CITY: MADISON
STATE: NJ
ZIP: 07940
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2013-02-10
0001022079
QUEST DIAGNOSTICS INC
DGX
0001222679
PREVOZNIK MICHAEL E
C/O QUEST DIAGNOSTICS INCORPORATED
3 GIRALDA FARMS
MADISON
NJ
07940
1
SVP & General Counsel
Common Stock
2013-02-10
4
F
0
1358
58.45
D
46867
D
Common Stock
2013-02-12
4
S
0
3481
57.4761
D
43386
D
Common Stock
4428
I
401k/SDCP
Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units.
The amount includes approximately 42 shares acquired via dividend reinvestment since the date of the last filing on Form 4 pursuant to a dividend reinvestment plan, sponsored by a broker-dealer, that essentially mirrors a dividend reinvestment plan sponsored by the registrant.
The amount includes exempt purchases made under the Company's stock purchase plan since the filing of the last Form 4.
These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k) and/or Supplemental Deferred Compensation Plan. The information was obtain from the plan administrator as of a recent date. The number of shares is based on the account balance of the Company stock fund under the plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 7, 2011.
This transaction was executed in multiple trades at prices ranging from $57.16 to $57.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Michael E. Prevoznik
2013-02-12